Partner with Santen

Partner with Santen Current partnerships Meet our EMEA business development team Partner with Santen Creating long-term, meaningful partnerships Current partnerships Working closely with companies, institutes and academia View Meet our EMEA business development team Get in touch to discuss a potential partnership with Santen View Why partner with Santen Long term, meaningful partnerships are key for Santen. As a medium-sized pharmaceutical company, we work collaboratively and efficiently to harness the expertise of innovative partner companies, research institutes and academia. This helps increase the pace and depth of R&D and give patients access to treatments faster. Patient need and customer satisfaction drive everything we do. It’s a responsive, entrepreneurial approach – we seek to improve eye health and vision in every way we can, from product adaptations to pioneering scientific discovery of treatments to tackling unmet medical needs.  We understand payer and patient needs for affordability in the healthcare economy and balance this with our desire to innovate to further benefit patients. As a fully integrated, globally positioned company, our world-class research and development centres, manufacturing sites and sales & marketing operations allow us to deliver innovative products that bring success to each and every one of our partnerships. Together with the development of internal pipeline and competencies, Santen EMEA is also considering external innovative ophthalmology programmes. This encompasses all projects offering an improvement to standard-of-care treatment outcomes, including cutting-edge technologies, revolutionary therapeutic approaches but also incrementally adding value to the existing portfolio. Area Strategic focus Retinal diseases Uveitis Age-related macular degeneration Branch retinal vein occlusion Diabetic macula oedema Glaucoma IOP reduction Compliance support Neuroprotection Ocular surface disorders Dry eye Corneal epithelial defects Orphan indications Unmet medical needs for small markets, narrow indications Drug delivery technologies Drug delivery technologies for sustained release Next: Current partnerships Back to top